866 related articles for article (PubMed ID: 25500159)
41. Anti-52 kDa Ro(SSA) autoantibodies in different autoimmune diseases preferentially recognize epitopes on the central region of the antigen.
Dorner T; Feist E; Wagenmann A; Kato T; Yamamoto K; Nishioka K; Burmester GR; Hiepe F
J Rheumatol; 1996 Mar; 23(3):462-8. PubMed ID: 8832984
[TBL] [Abstract][Full Text] [Related]
42. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
43. The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.
Cheng C; Jiang Y; Lu X; Gu F; Kang Z; Dai Y; Lu Z; Hu X
BMC Neurol; 2016 Oct; 16(1):203. PubMed ID: 27769253
[TBL] [Abstract][Full Text] [Related]
44. A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion.
Sawada J; Orimoto R; Misu T; Katayama T; Aizawa H; Asanome A; Takahashi K; Saito T; Anei R; Kamada K; Miyokawa N; Takahashi T; Fujihara K; Hasebe N
Mult Scler; 2014 Sep; 20(10):1413-6. PubMed ID: 24986696
[TBL] [Abstract][Full Text] [Related]
45. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
[TBL] [Abstract][Full Text] [Related]
46. Role of AQP4 Antibody Serostatus and its Prediction of Visual Outcome in Neuromyelitis Optica: A Systematic Review and Meta-Analysis.
Lin N; Liu Q; Wang X; Ma J; Li Y
Protein Pept Lett; 2017; 24(3):245-252. PubMed ID: 28071581
[TBL] [Abstract][Full Text] [Related]
47. The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.
Huang W; Tan H; Xia J; Li W; Li X; ZhangBao J; Chang X; Wang L; Wang M; Zhao C; Lu J; Lu C; Dong Q; Zhou L; Quan C;
Mult Scler Relat Disord; 2022 Oct; 66():104023. PubMed ID: 35843144
[TBL] [Abstract][Full Text] [Related]
48. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
Asgari N; Jarius S; Laustrup H; Skejoe HP; Lillevang ST; Weinshenker BG; Voss A
Mult Scler; 2018 Mar; 24(3):331-339. PubMed ID: 28326889
[TBL] [Abstract][Full Text] [Related]
49. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab.
Shidahara K; Hayashi K; Sada KE; Hiramatsu S; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
Lupus; 2018 Jul; 27(8):1374-1377. PubMed ID: 29498304
[TBL] [Abstract][Full Text] [Related]
50. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data.
Kopp CR; Prasad CB; Naidu S; Sharma V; Misra DP; Agarwal V; Sharma A
Lupus; 2023 Sep; 32(10):1164-1172. PubMed ID: 37487596
[TBL] [Abstract][Full Text] [Related]
51. [Seroprevalence and diagnostic value of aquaporin-4 antibody in patients with inflammatory central nervous system demyelinating diseases].
Wu L; Yang Y; Huang DH; Wu WP
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Feb; 31(2):350-2. PubMed ID: 21354891
[TBL] [Abstract][Full Text] [Related]
52. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay.
Hayakawa S; Mori M; Okuta A; Kamegawa A; Fujiyoshi Y; Yoshiyama Y; Mitsuoka K; Ishibashi K; Sasaki S; Hattori T; Kuwabara S
J Neuroimmunol; 2008 May; 196(1-2):181-7. PubMed ID: 18462810
[TBL] [Abstract][Full Text] [Related]
53. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Shiga Y; Kanaoka C; Fujimori J; Sato S; Itoyama Y
Brain; 2007 May; 130(Pt 5):1235-43. PubMed ID: 17449477
[TBL] [Abstract][Full Text] [Related]
54. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
Paul F; Jarius S; Aktas O; Bluthner M; Bauer O; Appelhans H; Franciotta D; Bergamaschi R; Littleton E; Palace J; Seelig HP; Hohlfeld R; Vincent A; Zipp F
PLoS Med; 2007 Apr; 4(4):e133. PubMed ID: 17439296
[TBL] [Abstract][Full Text] [Related]
55. Immunological follow-up of patients with neuromyelitis optica: is there a good biomarker?
Chanson JB; de Seze J; Eliaou JF; Vincent T
Lupus; 2013 Mar; 22(3):229-32. PubMed ID: 23172901
[TBL] [Abstract][Full Text] [Related]
56. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Isobe N; Yonekawa T; Matsushita T; Kawano Y; Masaki K; Yoshimura S; Fichna J; Chen S; Furmaniak J; Smith BR; Kira J
Mult Scler; 2012 Nov; 18(11):1541-51. PubMed ID: 22526930
[TBL] [Abstract][Full Text] [Related]
57. [Correlation of anti-60000 SSA antibody and anti-52000 SSA antibody with systemic lupus erythematosus and Sjögren's syndrome].
Zhang FC; Liu L; Xu D
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(1):7-10. PubMed ID: 17403303
[TBL] [Abstract][Full Text] [Related]
58. New coupled-particle light-scattering assay for detection of Ro/SSA (52 and 60 kilodaltons) and La/SSB autoantibodies in connective tissue diseases.
Bizzaro N; Bonelli F; Tonutti E; Tozzoli R; Villalta D
Clin Diagn Lab Immunol; 2001 Sep; 8(5):922-5. PubMed ID: 11527804
[TBL] [Abstract][Full Text] [Related]
59. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder.
Shimizu Y; Fujihara K; Ohashi T; Nakashima I; Yokoyama K; Ikeguch R; Takahashi T; Misu T; Shimizu S; Aoki M; Kitagawa K
Mult Scler; 2016 Oct; 22(11):1413-1420. PubMed ID: 25921053
[TBL] [Abstract][Full Text] [Related]
60. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
